{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:36:06Z","timestamp":1787337366593,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key Scientific and Technological Research Project of Henan Province","award":["252102311234"],"award-info":[{"award-number":["252102311234"]}]},{"name":"the Provincial Key Scientific Research Projects of Colleges and Universities of Henan","award":["25A350008"],"award-info":[{"award-number":["25A350008"]}]},{"name":"the State Key Laboratory of Cotton Bio-breeding and Integrated Utilization Open Fund","award":["CB2025A38"],"award-info":[{"award-number":["CB2025A38"]}]},{"name":"Key Laboratory of Advanced Drug Preparation Technologies,Ministry of Education of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02209-3","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:02:15Z","timestamp":1787331735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biguanide\u2011modified ursolic acid as a multifunctional lipid\u2011mimetic carrier of DOX liposome for synergistic chemotherapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-1711","authenticated-orcid":false,"given":"Yanzhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"3","key":"2209_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2209_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-024-01654-2","volume":"18","author":"Y Duan","year":"2025","unstructured":"Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025;18(1):10.","journal-title":"J Hematol Oncol"},{"key":"2209_CR3","doi-asserted-by":"publisher","first-page":"1683048","DOI":"10.3389\/fnut.2025.1683048","volume":"12","author":"Q Tian","year":"2025","unstructured":"Tian Q, Zheng Y, Li Y, Wu R, Lin Y, Chen Z. Global burden, trends, and inequalities of gastric cancer attributable to high-sodium diets: a 30-year analysis and projections based on the global burden of disease 2021 study. Front Nutr. 2025;12:1683048.","journal-title":"Front Nutr"},{"issue":"2","key":"2209_CR4","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","volume":"9","author":"K Shitara","year":"2024","unstructured":"Shitara K, Fleitas T, Kawakami H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 2024;9(2):102226.","journal-title":"ESMO Open"},{"issue":"5","key":"2209_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"2209_CR6","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.7150\/ijbs.113709","volume":"21","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xue F, Assaraf YG, Lin Y. Harnessing Natural Products to Surmount Drug Resistance in Gastric Cancer: Mechanisms and Therapeutic Perspectives. Int J Biol Sci. 2025;21(10):4604\u201328.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"2209_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ijc.34296","volume":"152","author":"T Liu","year":"2023","unstructured":"Liu T, Bai Y, Lin X, et al. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int J Cancer. 2023;152(4):749\u201360.","journal-title":"Int J Cancer"},{"issue":"11","key":"2209_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2209_CR9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/biomedicines11061772","volume":"11","author":"S Greco","year":"2023","unstructured":"Greco S, Fabbri N, Spaggiari R, De Giorgi A, Fabbian F, Giovine A. Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review. Biomedicines. 2023;11(6):1772.","journal-title":"Biomedicines"},{"key":"2209_CR10","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.redox.2024.103067","volume":"70","author":"Y Yang","year":"2024","unstructured":"Yang Y, Ren J, Zhang J, Shi H, Wang J, Yan Y. FTO ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via P53-P21\/Nrf2 activation in a HuR-dependent m6A manner. Redox Biol. 2024;70:103067.","journal-title":"Redox Biol"},{"issue":"1","key":"2209_CR11","doi-asserted-by":"publisher","first-page":"2545620","DOI":"10.1080\/14756366.2025.2545620","volume":"40","author":"P Guo","year":"2025","unstructured":"Guo P, Wu C, Wang T, et al. The key enzyme PYCR1 in proline metabolism: a dual driver of cancer progression and fibrotic remodeling. J Enzyme Inhib Med Chem. 2025;40(1):2545620.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"2209_CR12","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","volume":"77","author":"Y Du","year":"2025","unstructured":"Du Y, Karatekin F, Wang WK, Hong W, Boopathy G. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers. Pharmacol Rev. 2025;77(5):100076.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2209_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12951-025-03970-2","volume":"24","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zheng H, Yao W, et al. Spatiotemporally controlled delivery of biomacromolecules via injectable hydrogels for precision modulation of the tumor immune microenvironment. J Nanobiotechnol. 2025;24(1):82.","journal-title":"J Nanobiotechnol"},{"key":"2209_CR14","doi-asserted-by":"publisher","first-page":"e01671","DOI":"10.1002\/smtd.202501671","volume":"10","author":"HS Lee","year":"2026","unstructured":"Lee HS, Choo S, Chaudhary M, et al. Benchmarking Protein Nanoparticles for Drug Delivery and Clinical Translation. Small Methods. 2026;10:e01671.","journal-title":"Small Methods"},{"key":"2209_CR15","doi-asserted-by":"publisher","first-page":"123908","DOI":"10.1016\/j.biomaterials.2025.123908","volume":"328","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Hu Z, Wei Y, et al. Biomimetic cell membrane-mediated nanodelivery platform based on natural products: Emerging strategies for cancer combination therapy. Biomaterials. 2025;328:123908.","journal-title":"Biomaterials"},{"issue":"1","key":"2209_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1186\/s12951-025-03777-1","volume":"23","author":"F Araste","year":"2025","unstructured":"Araste F, Akbarzadeh M, Nabavinia MS. Multifunctional vesicles in cancer therapy and theranostics: current advances and future challenges. J Nanobiotechnol. 2025;23(1):785.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"2209_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41563-020-0676-x","volume":"19","author":"Challenging paradigms in","year":"2020","unstructured":"Challenging paradigms in. tumour drug delivery. Nat Mater. 2020;19(5):477.","journal-title":"Nat Mater"},{"issue":"20","key":"2209_CR18","doi-asserted-by":"publisher","first-page":"17010","DOI":"10.1021\/jacs.5c01214","volume":"147","author":"M Lin","year":"2025","unstructured":"Lin M, Liu D, Gong Y, et al. Bioactive Assembly Cofactor-Assisted Ursolic Acid Helix for Enhanced Anticancer Efficacy via In Situ Virus-like Transition. J Am Chem Soc. 2025;147(20):17010\u201321.","journal-title":"J Am Chem Soc"},{"key":"2209_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.foodres.2017.10.028","volume":"103","author":"L L\u00f3pez-Hortas","year":"2018","unstructured":"L\u00f3pez-Hortas L, P\u00e9rez-Larr\u00e1n P, Gonz\u00e1lez-Mu\u00f1oz MJ, Falqu\u00e9 E, Dom\u00ednguez H. Recent developments on the extraction and application of ursolic acid. A review. Food Res Int. 2018;103:130\u201349.","journal-title":"Food Res Int"},{"issue":"1","key":"2209_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1186\/s40001-025-03283-y","volume":"30","author":"F Xiang","year":"2025","unstructured":"Xiang F, Liu R, Gu Q, et al. Ursolic acid suppresses gastric cancer by targeting the miR-27a-3p\/Wnt\/\u03b2-catenin signaling axis. Eur J Med Res. 2025;30(1):1061.","journal-title":"Eur J Med Res"},{"key":"2209_CR21","doi-asserted-by":"publisher","first-page":"115278","DOI":"10.1016\/j.bcp.2022.115278","volume":"205","author":"F Luo","year":"2022","unstructured":"Luo F, Zhao J, Liu S, et al. Ursolic acid augments the chemosensitivity of drug-resistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction. Biochem Pharmacol. 2022;205:115278.","journal-title":"Biochem Pharmacol"},{"key":"2209_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jpba.2018.11.057","volume":"165","author":"L Zong","year":"2019","unstructured":"Zong L, Cheng G, Liu S, Pi Z, Liu Z, Song F. Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin. J Pharm Biomed Anal. 2019;165:268\u201375.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"2209_CR23","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1111\/jcmm.14130","volume":"23","author":"H Mu","year":"2019","unstructured":"Mu H, Liu H, Zhang J, et al. Ursolic acid prevents doxorubicin-induced cardiac toxicity in mice through eNOS activation and inhibition of eNOS uncoupling. J Cell Mol Med. 2019;23(3):2174\u201383.","journal-title":"J Cell Mol Med"},{"key":"2209_CR24","doi-asserted-by":"publisher","first-page":"178482","DOI":"10.1016\/j.ejphar.2025.178482","volume":"1012","author":"D Lin","year":"2025","unstructured":"Lin D, Dai X, Tang M, Wu Y, Xu H. Ursolic acid ameliorates doxorubicin-induced cardiotoxicity by inhibiting DRP1-mediated excessive mitochondrial fission and oxidative stress. Eur J Pharmacol. 2025;1012:178482.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2209_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","volume":"13","author":"J Szebeni","year":"2018","unstructured":"Szebeni J, Simberg D, Gonz\u00e1lez-Fern\u00e1ndez \u00c1, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100\u20138.","journal-title":"Nat Nanotechnol"},{"issue":"46","key":"2209_CR26","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1039\/C7TB02562A","volume":"5","author":"K Jiang","year":"2017","unstructured":"Jiang K, Han L, Guo Y, et al. A carrier-free dual-drug nanodelivery system functionalized with aptamer specific targeting HER2-overexpressing cancer cells. J Mater Chem B. 2017;5(46):9121\u20139.","journal-title":"J Mater Chem B"},{"key":"2209_CR27","doi-asserted-by":"publisher","first-page":"121897","DOI":"10.1016\/j.carbpol.2024.121897","volume":"332","author":"Y Guo","year":"2024","unstructured":"Guo Y, Yang X, Zhang Y, et al. Hyaluronic acid\/dextran-based polymeric micelles co-delivering ursolic acid and doxorubicin to mitochondria for potentiating chemotherapy in MDR cancer. Carbohydr Polym. 2024;332:121897.","journal-title":"Carbohydr Polym"},{"issue":"5","key":"2209_CR28","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1021\/acsbiomaterials.3c00218","volume":"9","author":"C Ning","year":"2023","unstructured":"Ning C, Dong Y, Yang K, Li X, Wang F, Zhang Y. Co-Encapsulation of Hydrophilic and Hydrophobic Drugs into Human H Chain Ferritin Nanocarrier Enhances Antitumor Efficacy. ACS Biomater Sci Eng. 2023;9(5):2572\u201383.","journal-title":"ACS Biomater Sci Eng"},{"key":"2209_CR29","doi-asserted-by":"publisher","first-page":"121509","DOI":"10.1016\/j.ijpharm.2022.121509","volume":"615","author":"Y Wang","year":"2022","unstructured":"Wang Y, Sun C, Huang L, et al. Magnolol-loaded cholesteryl biguanide conjugate hydrochloride nanoparticles for triple-negative breast cancer therapy. Int J Pharm. 2022;615:121509.","journal-title":"Int J Pharm"},{"issue":"3","key":"2209_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s13346-023-01433-5","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang L, Chang H, et al. Enhancing anti-tumor therapy with agmatine-cholesterol conjugate liposomes: in vitro and in vivo evidence. Drug Deliv Transl Res. 2024;14(3):788\u2013801.","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"2209_CR31","doi-asserted-by":"publisher","first-page":"100904","DOI":"10.1016\/j.jpha.2023.11.011","volume":"14","author":"B Chen","year":"2024","unstructured":"Chen B, Zhao Y, Lin Z, et al. Apatinib and gamabufotalin co-loaded lipid\/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis. J Pharm Anal. 2024;14(5):100904.","journal-title":"J Pharm Anal"},{"issue":"4","key":"2209_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semcancer.2008.03.005","volume":"18","author":"RH Tammi","year":"2008","unstructured":"Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol. 2008;18(4):288\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2209_CR33","doi-asserted-by":"publisher","first-page":"94907906","DOI":"10.26599\/NR.2025.94907906","volume":"18","author":"Q Guan","year":"2025","unstructured":"Guan Q, Chen R, Tian Z, Zhang P, Liu L, Cheng M, Zeng Y, Wu D, Zhou M, Dou H. Electrostatic attraction-directed membrane anchoring as a universal tool to enhance nanocarrier uptake into drug-resistant cancer cells. Nano Res. 2025;18(11):94907906.","journal-title":"Nano Res"},{"issue":"1","key":"2209_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/acs.molpharmaceut.5c00826","volume":"23","author":"Y Wang","year":"2026","unstructured":"Wang Y, Sun S, Liu M, Zhang S, Zheng J, Liu H. Glycyrrhetinic Acid-Biguanide Conjugate-Based Nanoparticles as a Multi-Functional Drug Delivery System: Paclitaxel Encapsulation and Targeted Therapy. Mol Pharm. 2026;23(1):224\u201338.","journal-title":"Mol Pharm"},{"key":"2209_CR35","doi-asserted-by":"publisher","first-page":"809714","DOI":"10.1155\/2015\/809714","volume":"2015","author":"Z Qian","year":"2015","unstructured":"Qian Z, Wang X, Song Z, et al. A phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors. Biomed Res Int. 2015;2015:809714.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2209_CR36","first-page":"385","volume":"15","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhang Y, Zhang Y, et al. Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil\u00ae. Asian J Pharm Sci. 2020;15(3):385\u201396.","journal-title":"Asian J Pharm Sci"},{"key":"2209_CR37","doi-asserted-by":"publisher","first-page":"124659","DOI":"10.1016\/j.ijpharm.2024.124659","volume":"665","author":"J Lian","year":"2024","unstructured":"Lian J, Tang X, Gui Y, Lu S, Song Y, Deng Y. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome. Int J Pharm. 2024;665:124659.","journal-title":"Int J Pharm"},{"issue":"12","key":"2209_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","volume":"3","author":"G Batist","year":"2002","unstructured":"Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002;3(12):1739\u201351.","journal-title":"Expert Opin Pharmacother"},{"issue":"37","key":"2209_CR39","doi-asserted-by":"publisher","first-page":"48969","DOI":"10.1021\/acsami.4c06720","volume":"16","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang CL, Liu H, et al. Percutaneous Delivery of Hederacoside C-Loaded Nanoliposome Gel Alleviates Psoriasiform Skin Inflammation through the CCL17\/Treg Axis. ACS Appl Mater Interfaces. 2024;16(37):48969\u201381.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"2209_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/08982104.2015.1117489","volume":"26","author":"SR Paliwal","year":"2016","unstructured":"Paliwal SR, Paliwal R, Agrawal GP, Vyas SP. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin. J Liposome Res. 2016;26(4):276\u201387.","journal-title":"J Liposome Res"},{"key":"2209_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.colsurfb.2017.02.018","volume":"153","author":"Y Niu","year":"2017","unstructured":"Niu Y, Stadler FJ, Song J, Chen S, Chen S. Facile fabrication of polyurethane microcapsules carriers for tracing cellular internalization and intracellular pH-triggered drug release. Colloids Surf B Biointerfaces. 2017;153:160\u20137.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"34","key":"2209_CR42","doi-asserted-by":"publisher","first-page":"9343","DOI":"10.1016\/j.biomaterials.2014.07.043","volume":"35","author":"A Ediriwickrema","year":"2014","unstructured":"Ediriwickrema A, Zhou J, Deng Y, Saltzman WM. Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials. 2014;35(34):9343\u201354.","journal-title":"Biomaterials"},{"issue":"2","key":"2209_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3892\/ol.2016.5473","volume":"13","author":"G Liang","year":"2017","unstructured":"Liang G, Li S, Du W, Ke Q, Cai J, Yang J. Hypoxia regulates CD44 expression via hypoxia-inducible factor-1\u03b1 in human gastric cancer cells. Oncol Lett. 2017;13(2):967\u201372.","journal-title":"Oncol Lett"},{"issue":"6","key":"2209_CR44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s13402-023-00835-4","volume":"46","author":"H Deng","year":"2023","unstructured":"Deng H, Gao J, Cao B, et al. LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing. Cell Oncol (Dordr). 2023;46(6):1675\u201390.","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"2209_CR45","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.4161\/15548627.2014.981790","volume":"10","author":"S Deegan","year":"2014","unstructured":"Deegan S, Saveljeva S, Logue SE, et al. Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions. Autophagy. 2014;10(11):1921\u201336.","journal-title":"Autophagy"},{"issue":"12","key":"2209_CR46","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/neuonc\/noaa105","volume":"22","author":"RY Huang","year":"2020","unstructured":"Huang RY, Young RJ, Ellingson BM, et al. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020;22(12):1822\u201330.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2209_CR47","doi-asserted-by":"publisher","first-page":"e2399","DOI":"10.1002\/pst.2399","volume":"24","author":"V Bonato","year":"2025","unstructured":"Bonato V, Tang SY, Hsieh M, Zhang Y, Deng S. Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies. Pharm Stat. 2025;24(1):e2399.","journal-title":"Pharm Stat"},{"key":"2209_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2023.03.001","volume":"356","author":"C Xu","year":"2023","unstructured":"Xu C, Li S, Chen J, et al. Doxorubicin and erastin co-loaded hydroxyethyl starch-polycaprolactone nanoparticles for synergistic cancer therapy. J Control Release. 2023;356:256\u201371.","journal-title":"J Control Release"},{"key":"2209_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jconrel.2022.04.031","volume":"346","author":"M Hashida","year":"2022","unstructured":"Hashida M. Advocation and advancements of EPR effect theory in drug delivery science: A commentary. J Control Release. 2022;346:355\u20137.","journal-title":"J Control Release"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02209-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02209-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02209-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:02:44Z","timestamp":1787335364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02209-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":49,"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02209-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experimental procedures were performed in strict accordance with the institutional guidelines for laboratory animal welfare and were approved by the Institutional Animal Care and Use Committee of the university (Approval No. yxyllsc20250145).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare a granted patent related to the reported formulation system. No other competing interests exist.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}